Navigation Links
Spherix Expands Phase 3 Naturlose Diabetes Trial Outside of the U.S.
Date:7/14/2008

enhance recruitment and compliance in the trial. This is a significant advancement for the Company, our investigators and their patients," said Mr. Brown.

1. Yongming Lu, Gilbert Levin, Thomas Donner. "Tagatose, a New Anti-Diabetic and Obesity-Control Drug." Diabetes, Obesity and Metabolism. 10, 2008, 109-134.

2. Meredith Cohn, "Sweet Hope, The natural sugar tagatose, once a Slurpee sweetener, could help diabetes patients control blood glucose levels." Baltimore Sun, March 27, 2008.

3. Sugar Treatment Could Help Diabetes Patients, Jun 30, 2008 8:21 pm US/Eastern, http://kdka.com/health/sugar.diabetes.Tagatose.2.760164.html (click on "Related" to watch the video).

Certain statements contained herein are "forward looking" statements as defined in the Private Securities Litigation Reform Act of 1995. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied. Factors that could cause actual results to differ materially from those expressed or implied include, but are not limited to, those discussed in filings by the Company with the Securities and Exchange Commission, including the filing on Form 8-K made on October 10, 2007.

Spherix's mission is to create value and increase shareholder wealth through innovations that benefit our clients and the human condition. Spherix offers innovations in biotechnology, and provides technical and regulatory consulting services to biotechnology and pharmaceutical companies.

Spherix's Internet address is http://www.spherix.com.


'/>"/>
SOURCE Spherix Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Spherix D-tagatose to be Supplied by Inalco SpA
2. Growth Achieved in Spherixs Health Sciences Consulting Business
3. Spherix Reports Second Quarter Earnings
4. Cardinal Health Expands PET Nuclear Pharmacy Services to Support Clinical Drug Trials
5. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
6. BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, With Phase 2 Trial in Uterine Cancer
7. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
8. CoreSpine Technologies Expands Spinal Disc Site Preparation Efforts
9. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
10. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
11. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  CytoSorbents Corporation (NASDAQ CM: ... CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation ... receipt of $385,642, net of transaction costs, in ... Technology Business Tax Certificate Transfer Program sponsored by ...
(Date:1/22/2015)... CLEVELAND , Jan. 22, 2015  ViewRay™, a privately ... entered into an exclusive distributor agreement with ITOCHU Corporation ... radiation therapy system for the treatment of cancer in ... (me-rid-i-an) system, is the world,s first and only MRI-guided ...
(Date:1/22/2015)...  Amgen (NASDAQ: AMGN ) today announced that it will ... Tuesday, Jan. 27, 2015, after the close of the U.S. financial ... the investment community at 2 p.m. PT. Participating in the call ... chief executive officer, and other members of Amgen,s senior management team. ...
Breaking Medicine Technology:CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2
... 8 Group Practice Forum (GPF), an independent network ... Fromer-GPF Patient Journey , a proprietary workflow solution designed ... patient care.  The Journey was developed by the ... FAAFP, who also serves as Assistant Clinical Professor of Family ...
... Protectus Medical Devices, Inc. (OTCQB: PTMD), developer and marketer of innovative safety ... US Patent and Trademark Office on its patent application describing a spring-activated, ... it becoming the gold standard in safety syringe devices.  , ... Dr. John Salstrom , CEO, ...
Cached Medicine Technology:Group Practice Forum Launches Fromer-GPF Patient Journey Providing Physicians with Simple Solutions to Improve Patient Care 2US Patent Allowed for Spring Action That Separates Protectus Innovative Safety Syringe From All Others 2US Patent Allowed for Spring Action That Separates Protectus Innovative Safety Syringe From All Others 3
(Date:1/22/2015)... 2015 Thousand of GranuFlo lawsuits ( ... its GranuFlo and NaturaLyte dialysis concentrates continue to move ... District Court, District of Massachusetts, Bernstein Liebhard LLP reports. ... has remanded a case filed by the state of ...
(Date:1/22/2015)... released a new blog post presenting the basic features of ... an accidental death and dismemberment rider for a car insurance ... benefits if the insured dies in an accident. Accidental death ... insurance. , AD&D is not expensive and can be ...
(Date:1/22/2015)... 2015 Yesterday, Senator Holly Mitchell ... Kristin Olsen (R-Modesto) were honored by the California ... biotechnology, biomedical science, medical device and pharmaceutical innovation ... the “2014 Life Sciences Champion” award from CHI ...
(Date:1/22/2015)... Four years since the release of their debut recording ... marriage of Avasa & Matthew Love – the duo are pleased ... release through White Swan Records on February 24, 2015. , THE ... path available to all of us to walk out of the ...
(Date:1/22/2015)... January 22, 2015 As interest in the ... care gains momentum worldwide, Rev. Eric J. Hall , ... Network (HCCN), will be the keynote speaker on January ... Israel’s public health system. , The conference, “Hope and Resilience: ...
Breaking Medicine News(10 mins):Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3
... discussions with FDA -, MENLO PARK, Calif., Dec. ... of customizable drug-eluting stent (DES),systems, today announced that it ... for CE Mark approval of its Custom NX DES,System., ... dossier and the,drug formulation submission from Biosensors International Group. ...
... ST. PAUL (December 26, 2007) University of Minnesota ... researchers have discovered a new fast-acting antidote to cyanide ... those who are exposed to the chemical namely ... cyanide antidotes work slowly and are ineffective when administered ...
... hay fever and other allergic reactions, by preventing the ... by scientists. Researchers hope their finding, published today (Thursday ... allow therapies to be developed that treat allergies by ... a gene known as GATA-3 can block the development ...
... Dec. 26 A lot of Americans take advantage ... to lose weight and live,healthier. There may be a ... that work focus on healthy long-term lifestyle changes., ... Registered journalists can access video, audio, text, graphics ...
... cell research to needle exchanges to medical marijuana and ... science, according to a new book by a leading ... Weill Cornell Medical College. , "Truth, Lies, and Public ... Collide" (Praeger Press, 2007) is authored by Dr. Madelon ...
... results are promising, they don,t address benefits of drug ... treatment that wipes out abnormal heart tissue reduces the ... implanted after heart attacks, a new trial showed. , ... it slips into abnormal rhythms, they are desirable to ...
Cached Medicine News:Health News:XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe 2Health News:XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe 3Health News:U of M researchers discover fast-acting cyanide antidote 2Health News:Fight against hay fever and other allergies helped by new immune system discovery 2Health News:Heart Procedure Reduces Need for Defibrillator Shocks 2Health News:Heart Procedure Reduces Need for Defibrillator Shocks 3
Sera available in three levels for the control of accuracy and precision for up to 31 analytes...
Human based material available in two levels for the control of accuracy and precision for upto 23 analytes....
CRP Liquid Conrtols level 3...
The IRN method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of iron in serum....
Medicine Products: